HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
- HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
- Accession Number
- ATC Classification
Drug Drug Description Trastuzumab A monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers. Trastuzumab emtansine An antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer. Pertuzumab An antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents. Trastuzumab deruxtecan An antibody used to treat certain types of unresectable or metastatic HER-2 positive breast cancer. Trastuzumab duocarmazine Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer). Margetuximab An Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
- Drugs & Drug Targets